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E-mail: m.maini@ucl.ac.ukCheckpoint inhibitors and adoptive cell therapy provide prom-
ising options for treating solid cancers such as HBV-related
HCC, but they have limitations. We tested the potential to
combine advantages of each approach, genetically reprogram-
ming T cells speciﬁc for viral tumor antigens to overcome
exhaustion by down-modulating the co-inhibitory receptor
PD-1. We developed a novel lentiviral transduction protocol
to achieve preferential targeting of endogenous or TCR-redir-
ected, antigen-speciﬁc CD8 T cells for shRNA knockdown of
PD-1 and tested functional consequences for antitumor immu-
nity. Antigen-speciﬁc and intrahepatic CD8 T cells transduced
with lentiviral (LV)-shPD-1 consistently had a marked reduc-
tion in PD-1 compared to those transduced with a control
lentiviral vector. PD-1 knockdown of human T cells rescued
antitumor effector function and promoted killing of hepatoma
cells in a 3D microdevice recapitulating the pro-inﬂammatory
PD-L1hi liver microenvironment. However, upon repetitive
stimulation, PD-1 knockdown drove T cell senescence and in-
duction of other co-inhibitory pathways. We provide the proof
of principle that T cells with endogenous or genetically engi-
neered speciﬁcity for HBV-associated HCC viral antigens can
be targeted for functional genetic editing. We show that
PD-1 knockdown enhances immediate tumor killing but is
limited by compensatory engagement of alternative co-inhibi-
tory and senescence program upon repetitive stimulation.
INTRODUCTION
CD8 T cells are critical for immune control of persistent viral infec-
tions and cancer. In both these settings, T cell efﬁcacy is limited by
low frequencies and functional defects, which are promoted by
chronic exposure to antigen and/or inﬂammation, a scenario termed
exhaustion.1 A cardinal feature of exhausted T cells is excessive nega-
tive co-regulation through multiple receptors, with PD-1 constituting
a pivotal co-inhibitory receptor in these settings.1,2 The capacity to
restore immune control of infection and cancer by in vivo PD-1
blockade was ﬁrst demonstrated in animal studies and more recentlyMolecular
This is an open access article under thexempliﬁed by ground-breaking results in patients with melanoma
and other solid tumors.1–3 Although the use of checkpoint inhibitors
such as PD-1 blocking antibodies is revolutionizing cancer therapy
for a proportion of patients, there remain signiﬁcant limitations
inherent to this approach. A therapeutic response to antibody-medi-
ated checkpoint blockade requires the tumor to have a relatively high
mutation burden and a pre-existing lymphocytic inﬁltrate.4–6 The use
of blocking monoclonal antibodies means that effects are of limited
duration and require repeated dosing, with its associated problems.
Cells expressing PD-1 will potentially be affected, resulting in the un-
leashing of bystander and autoreactive T cell speciﬁcities and a sub-
stantial risk of autoimmune disease.7 Regulatory populations such
as Tregs can also express high levels of PD-1, so PD-1 blockade can
expand regulatory T cells (Tregs), which will tend to counteract the
boosting of effector T cells.8
A potentially elegant solution for these limitations is to attempt selec-
tive genetic knockdown of PD-1 on T cells of the desired speciﬁcity.
To date, genetic engineering of T cells has targeted mitogen-activated
bulk T cells, rather than those of a particular speciﬁcity. This could
result in genetic modiﬁcation of irrelevant and potentially harmful
subsets and speciﬁcities, as in the use of blocking antibodies. In addi-
tion, inefﬁcient transduction rates may mean that low-frequency,
antigen-speciﬁc T cells are not targeted. In this study, we have inves-
tigated two approaches to achieving selective knockdown of PD-1 on
antigen-speciﬁc T cells. First, we have developed a protocol to focusTherapy Vol. 26 No 11 November 2018 ª 2018 The Authors. 2553
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Molecular Therapylentiviral transduction of short hairpin RNAs (shRNAs) on peptide-
speciﬁc T cells. Second, we have combined PD-1 knockdown with
TCR gene transfer to confer antigen speciﬁcity.
As a proof of principle for these novel approaches, we have used
commonly targeted human leukocyte antigen (HLA)-A2-restricted
epitopes within HBV proteins. These targets are of major clinical rele-
vance in the development of T cell therapy for chronic hepatitis B
(CHB) and HBV-related hepatocellular carcinoma (HCC).9 CHB
and HCC are characterized by very low-frequency, antigen-speciﬁc
CD8 T cell responses expressing high levels of PD-1.10–13 HBV-
related HCC often has integrated HBV DNA and can express HBV
antigens, rendering it susceptible to killing by HBV-speciﬁc T cells.9
We contributed to the ﬁrst-in-man use of TCR-redirected T cells to
treat a patient with HBsAg-expressing HCC metastases.14 This case
supported the feasibility and safety of using HBV-speciﬁc adoptive
T cell therapy in HCC. However, such autologous TCR gene-trans-
ferred T cells remain susceptible to inactivation through their expres-
sion of PD-1 in analogous settings.15–18
In the current study, we therefore edit PD-1 expression to favor the
survival of either endogenous or TCR-redirected, tumor-speciﬁc
T cells within the PD-L1hi environment characteristic of the liver
and tumors.2,19,20 We show that it is feasible to target endogenous
and TCR-redirected, virus-speciﬁc T cells with a lentivirus vector car-
rying shRNA to knock down PD-1. In light of accumulating evidence
that tissue and tumor-resident T cells harbor unique adaptations to
their niche,21,22 we also test the feasibility to carry out genetic modi-
ﬁcation of liver-extracted T cells. We demonstrate that PD-1 knock-
down on HBV-associated, HCC antigen-speciﬁc T cells boosts their
effector function and capacity to kill tumor cells in a PD-L1hi 3D mi-
croﬂuidic system. However, we ﬁnd that PD-1 knockdown also limits
the capacity of human CD8 T cells to withstand repetitive TCR stim-
ulation and drives compensatory engagement of an alternative co-
inhibitory and senescence program.
RESULTS
Preferential Targeting of Virus-Specific T Cells for Genetic
Manipulation
T cells directed against an antigenic target constitute a small fraction
of the global population. We investigated whether it was possible to
direct lentiviral transduction toward these small, endogenous T cell
populations of a particular speciﬁcity and thus achieve their selective
genetic manipulation while sparing the remaining T cells. Because
lentiviral transduction favors T cells transitioning into the G1b phase
of the cell cycle,23 we replaced the prototype polyclonal T cell activa-
tion protocol with stimulation using peptides representing viral
epitopes.
We initially tested the possibility of targeting cytomegalovirus
(CMV)-speciﬁc CD8 T cells, because these are an important thera-
peutic target and a useful test population, with a highly conserved
immunodominant HLA-A2-restricted response that is usually detect-
able in the circulation at much higher frequencies than HBV-speciﬁc2554 Molecular Therapy Vol. 26 No 11 November 2018CD8 T cells. Pre-stimulation of isolated CD8 T cells with CMV pep-
tide NLV for 24 hr was successful in focusing vesicular stomatitis
virus G-protein (VSV-g) pseudotyped lentiviral transduction on the
responding (interferon g+ [IFN-g+]) population (Figure 1A). Up
to 67.6% of the CMV-speciﬁc CD8 T cells were transduced with a
GFP-expressing control lentivirus, whereas only a minimal propor-
tion of the global CD8 T cells were transduced (0.5% to 4.4%
GFP+) (Figure 1A). Addition of the cytokine IL-15 tended to increase
the expansion of virus-speciﬁc CD8 T cells (as previously described24)
but at the expense of some increase in background transduction of
global CD8 (Figures 1A and S1A). Staining with an HLA-A2/NLV
peptide dextramer conﬁrmed preferential transduction of more
than 60% of CMV-speciﬁc CD8 T cells (Figures 1B and S1B).
We then tested the feasibility of speciﬁcally transducing the small
populations of HBV-speciﬁc CD8 T cells circulating in patients
with chronic HBV infection using the same protocol. As seen with
CD8 T cells directed against CMV, there was enrichment for trans-
duction of HBV-speciﬁc CD8 T cells compared to the global fraction
(Figure 1C). The percentage of transduced (GFP+) HBV-speciﬁc CD8
T cells tended to increase in the presence of interleukin-15 (IL-15),
reaching up to 63.2% of IFN-g-expressing cells. Furthermore, efﬁ-
cient transduction of HBV-speciﬁc CD8 T cells could be achieved
stimulating whole peripheral blood mononuclear cell (PBMC) rather
than puriﬁed CD8 T cells (Figure 1D). These experiments conﬁrmed
that it was possible to target lentiviral transduction toward CD8
T cells speciﬁc for HBV antigens commonly expressed by HCC.
This was consistently achieved for the more robust responses directed
against CMV but was also feasible to a variable degree for low-fre-
quency, HBV-speciﬁc T cells.
PD-1 Knockdown on Human Antigen-Specific T Cells
Having developed a protocol for targeted transduction of antigen-
speciﬁc T cells, we then tested the potential to introduce shRNAs
for their molecular modiﬁcation. We focused on knockdown of the
co-inhibitory receptor PD-1, an important therapeutic target in
chronic viral infection and cancer. We ﬁrst tested the capacity of len-
tiviral vectors carrying GFP and either shRNA against PD-1 (lentivi-
ral [LV]-shPD-1) or control shRNA (LV-shCTR) to knock down
PD-1 on global human CD8 T cells. shPD-1 (Sigma) was designed
to maximize efﬁcient knockdown of only the target gene and was
not predicted to target any off-target transcripts on screening using
GESS or SPICE. The percentage of transduced (GFP+) CD8 T cells
expressing PD-1 was signiﬁcantly reduced by LV-shPD-1 compared
to LV-shCTR (ﬂow cytometry plots and summary data, Figure 2A)
(qPCR, Figure S2A). Consistent with the capacity of lentiviral-trans-
duced shRNA to achieve long-term silencing of genes, stable PD-1
knockdown was maintained over 2 weeks in culture (Figure S2B).
We next tested shRNA knockdown of PD-1 using peptide-stimulated
lentiviral transduction of endogenous virus-speciﬁc T cells. Peptide-
loaded T2 cells were used to restimulate genetically manipulated
CD8 T cells. CMV-speciﬁc CD8 T cells, identiﬁed by IFN-g staining
(Figure 2B) or HLA-A2/NLV dextramer staining (Figure 2C)
Figure 1. Selective Lentiviral Transduction of Virus-Specific CD8 T Cells
Isolated CD8 T cells were stimulated with HLA-A2-restricted viral peptides ± IL-15 for 24 hr. Cells were then transduced with lentiviral particles expressing GFP ± a control
shRNA (LV-shCTR) and cultured for 7 days. (A and B) Representative examples of GFP expression in global CD8 T cells and in CMV-specific CD8 T cells gated on intracellular
IFN-g+ (A) and HLA-A2/NLV-dextramer+ (B) CD8 T cells upon restimulation with NLV-loaded T2 cells. Summary data comparing GFP expression in global and CMV-specific
CD8 T cells (n = 4 healthy control [HC] and n = 1 CHB). Data were analyzed with paired t test. (C) GFP expression in global CD8 T cells and in HBV-specific CD8 T cells gated
on intracellular IFN-g+CD8 T cells upon restimulation with HBV/HLA-A2+ peptide-loaded T2 cells. Non-peptide-loaded T2 cells were used to restimulate T cells as a control
for non-specific background IFN-g staining, which was subtracted from that obtained using NLV or HBV peptide-loaded T2 cells. Summary data comparing GFP expression
in global and HBV-specific CD8 T cells (n = 8, CHB). Data were analyzed with one-way ANOVA and Dunn’s multiple comparison test. (D) PBMCs from CHB patients (n = 3)
were lentivirally transduced (without purifying CD8 T cells) after 24 hr of stimulation, with overlapping peptides spanning the HBV core plus IL-15, and cultured for 10 days.
Representative dot plots of GFP expression in global and in IFN-g + CD8 T cells after restimulation with HBV core-overlapping peptides and summary data. In (A)–(C), CD8+
T cells were pre-gated on live/CD19/CD3+, whereas in (D), CD8 T cells were pre-gated on live+/CD3+/CD4. Significant differences are yp < 0.1 and *p < 0.05.
www.moleculartherapy.orgfollowing 24 hr stimulation with peptide and IL-15, were transduced
with lentiviral vectors. A high proportion of transduced GFP+ cells
expressed PD-1 with LV-shCTR (up to 91.8%), whereas PD-1 expres-
sion was almost abrogated using LV-shPD-1 (Figures 2B and 2C).
Similarly, PD-1 expression was partially abrogated on low-frequency
HBV-speciﬁc CD8 T cells (Figure 2D).
PD-1 Knockdown of TCR-Redirected Peripheral and Liver-
Infiltrating T Cells
To overcome the limitation of the very low-frequency of HBV-spe-
ciﬁc CD8 T cells in patients with CHB and HBV-related HCC, it is
possible to reengineer T cells able to recognize HBV epitopes by
TCR gene transfer.14,25 However, adoptively transferred T cells
have been shown to remain susceptible to PD-1-mediated exhaustion
in vivo.15–17We therefore tested the possibility of dual genetic manip-
ulation of human CD8 T cells to render them both speciﬁc for HBV
and resistant to PD-1 inhibition. T cells engineered to express a TCR
speciﬁc for anHLA-A2-restricted epitope fromHBV core or envelope
(core18–27 or env183-91, using a retroviral vector as described previ-
ously25) were identiﬁed and underwent ﬂuorescence-activated cell
sorting (FACS) based on their expression of the murine portion of
the Cb chain (CbmTCR) (Figure 3A). Puriﬁed TCR-redirected
T cells were then transduced with lentiviral vectors carrying shCTR.This conﬁrmed the feasibility of dual transduction; cells remained
viable and functional, producing high levels of IFN-g and tumor ne-
crosis factor alpha (TNF-a) upon stimulation with the T2 cell line
loaded with cognate peptide (Figure 3B). We then tested whether
we were able to reduce PD-1 expression on TCR-transduced T cells
following a second transduction using LV-shPD-1. T cells redirected
against either core18–27 or env183-91, identiﬁed by staining for
CbmTCR or an HLA-A2/env183-91 dextramer, showed reduced
PD-1 following a second transduction with LV-shPD-1 compared
to LV-shCTR (Figures 3C and 3D).
The literature has highlighted the unique properties of tissue-resident
immune cells,21,22 which could potentially be exploited to promote
retention and survival of genetically modiﬁed T cells at the site of in-
terest. Tumor-inﬁltrating lymphocytes have previously been ex-
tracted and expanded for adoptive therapy to enrich for T cells
with the correct speciﬁcity and homing characteristics.26 We there-
fore tested whether it was possible to genetically modify liver-resident
T cells, which are adapted to persist at the site of HBV and HCC dis-
ease. For this purpose, intrahepatic T cells were extracted from bi-
opsies of HBV-infected livers, healthy liver perfusates, or margins
of liver cancer resections; stimulated with a cocktail of cytokines
known to promote liver residence;21 and transduced with LV-shCTR.Molecular Therapy Vol. 26 No 11 November 2018 2555
Figure 2. PD-1 Knockdown on Virus-Specific CD8 T Cells
PD-1 levels were analyzed in antigen-specific CD8 T cells after peptide-stimulated transduction with a lentiviral vector expressing a short hairpin against PD-1 (LV-shPD-1) or
a control shRNA (LV-shCTR). (A) Representative FACS dot plot of PD-1 expression on global GFP+CD8 T cells and summary data (n = 4 HC and n = 9 CHB) (p = 0.0002,
Wilcoxon rank-sum test). Seven days after lentiviral transduction, virus-specific CD8 T cells were identified by IFN-g production and HLA-A2-peptide dextramer staining. (B
and C) Lentiviral transduced CMV-specific CD8 T cells were analyzed for PD-1 expression on IFN-g+ (B) and HLA-A2/NLV-dextramer+ (C) CD8 T cells after stimulation with
NLV peptide-loaded T2 cells. Summary data of GFP+CMV-specific CD8 T cells (n = 2 HC and n = 2CHB for IFN-g+ responses and n = 1HC and n = 2CHB for HLA-A2/NLV-
dextramer+ staining). (D) PD-1 expression in HBV-specific CD8 T cells after lentiviral transduction analyzed on IFN-g+ CD8 after stimulation with HBV/HLA-A2+ peptide-
loaded T2 cells. Summary data of PD-1 levels on GFP+HBV-specific CD8 T cells from CHB patients (n = 3). Data were analyzed with Wilcoxon rank-sum test. CD8 T cells
were pre-gated on live+/CD19/CD3+. Significant differences are <0.1: ***p < 0.001. Any p value less than 0.001 was designated with three asterisks.
Molecular TherapyCD8 T cells extracted from these diverse liver samples could all be
successfully transduced to achieve a mean expression of 36.8%
GFP+ (Figure 3E). In some cases, we also transduced intrahepatic
lymphocytes with LV-shPD-1, demonstrating partial knockdown of
PD-1 (Figure 3F).
PD-1 Knockdown Increases CD8 T Cell Cytokine Release and
Proliferation
To examine the potential of PD-1 knockdown to boost antitumor
capacity of T cells, we ﬁrst analyzed the impact on T cell effector
function in standard 2D culture assays, in which some PD-L1 will
be upregulated.27 PBMC from patients with CHB were lentivirally
transduced, expanded twice with a-CD3/CD28 antibodies for
15 days, and restimulated with a-CD3/CD28 antibodies. IFN-g-pro-
ducing and IFN-gTNF-a dual-producing CD8 T cells were
signiﬁcantly increased following repetitive stimulation of those pop-
ulations transduced with LV-shPD-1 compared to LV-shCTR (Fig-2556 Molecular Therapy Vol. 26 No 11 November 2018ures 4A and 4B). Similarly, CD8 T cells with PD-1 knockdown
displayed enhanced expression of the key cytotoxic mediator gran-
zyme B expression and of Ki67, a marker of cell proliferation,
compared to control CD8 T cells (Figures 4C and 4D). PD-1 knock-
down resulted in an initial upregulation of T-bet (Figures 4E and 4F),
with the degree of induction correlating positively with IFN-g pro-
duction (Figure 4G).
Enhanced Antitumor Response in a 3D Model of the PD-L1hi
Liver Microenvironment
As demonstrated in our previous work,28 classical 2D in vitro assays
have limitations in evaluating the killing efﬁciency of engineered
T cells. Therefore, to examine the antitumor potential of HBV-redir-
ected, PD-1 knockdown engineered T cells, we used an innovative 3D
microﬂuidic model, in which hepatoma cells expressing HBV preS1
protein covalently linked to GFP are seeded in a collagen gel in the
central region of the device and T cells are injected into an
Figure 3. PD-1 Knockdown on HBV TCR-Redirected CD8 T Cells from the Intrahepatic and Peripheral Compartment
(A) FACS dot plots showing non-transduced and HBV core18–27TCR CD8 T cells from a healthy donor before sorting. TCR expression was analyzed by the expression of
murine Cb region (CbmTCR). (B) Sorted TCR-redirected CD8 T cells were activated and transduced with LV-shCTR. After 7 days, the frequency of IFN-g-TNF-a levels gated
on GFP+CbmTCR+ was measured after stimulation with HBc18–27 peptide-loaded T2 cells. (C) Representative FACS dot plots of PD-1 expression on GFP+CbmTCR+ CD8
T cells from a healthy donor after transduction of HBV core18–27/env182-191TCR with LV-shCTR or LV-shPD-1. (D) PD-1 levels in GFP+ HBV env183-191TCR-redirected CD8
T cells gated on dextramer+ CD8 cells. Intrahepatic lymphocytes were activated for 24 hr with a cocktail of cytokines and transduced with LV-shCTR. (E) Representative
FACS dot plots and summary data of the frequency of intrahepatic GFP+ CD8 T cells. (F) Representative FACS dot plots and summary data of PD-1 expression on in-
trahepatic CD8 T cells transduced with LV-shCTR or LV-shPD-1 (n = 5). Data were analyzed withWilcoxon rank-sum test. CD8 T cells were pre-gated on live+/CD3+/CD4,
and in the case of restimulation with peptide-loaded T2 cells or dextramer staining, CD19-positive cells were excluded.
www.moleculartherapy.orgadjacent medium channel.28 PBMCs from four healthy donors were
transduced with LV-shCTR or LV-shPD-1 and expanded for
15 days before env183–191TCR mRNA electroporation. Following
ﬂow cytometric conﬁrmation of efﬁcient lentiviral transduction and
mRNA electroporation (55.7% to 73.9% HBV-TCR+CD3), cells
were injected into the 3D microﬂuidic system (Figure 5A).
We have shown that the pro-inﬂammatory cytokines IFN-g, TNF-a,
and IL-2 enhance the capacity of TCR-transfected T cells to lyse tu-mor target cells;28 by contrast, the addition of autologous monocytes
mimics the PD-L1hi environment of the liver.29 We therefore recapit-
ulated these conditions in the microﬂuidic system to evaluate the
beneﬁt of PD-1 knockdown. First, we conﬁrmed that target cell killing
by env183–191TCR-redirected T cells was increased in the presence of
cytokines and inhibited when autologous monocytes were embedded
in the collagen gel (Figures S3A and S3B), whereas mock-TCR-trans-
duced T cells showed only basal tumor death (Figures S3C and S3D).
PD-L1 was upregulated both on target tumor cells and on CD14+Molecular Therapy Vol. 26 No 11 November 2018 2557
Figure 4. Functional Characterization of CD8 T Cells with PD-1 Knockdown
Activated PBMCs from CHB patients were transduced with LV-shCTR or LV-shPD-1 and then expanded with a-CD3/CD28 antibodies for 15 days. CD8 T cells responses
were then analyzed after overnight a-CD3/CD28 stimulation. (A–D) Representative FACS dot plots and summary data showing the production of IFN-g (A), IFN-g-TNF-a (B),
granzyme B (C) (n = 8, CHB), and Ki67 (D) (n = 8, CHB) from GFP+ CD8 T cells transduced with LV-shCTR or LV-shPD-1. (E and F) T-bet expression (E) and geometric mean
fluorescent intensity (gMFI) (F) (n = 4, CHB) fromGFP+ CD8+ T cells transduced with LV-shCTR or LV-shPD-1. (G) T-bet expressing according to the IFN-g production (n = 8,
CHB). CD8 T cells were pre-gated on live+/CD3+/CD4 and, in the case of (C), on GFP+. (A)–(F) were analyzed with Wilcoxon rank-sum test; (G) was analyzed with Pearson
product-moment correlation coefficient. Significant differences are <0.1: *p < 0.05 and **p < 0.01. Error bars indicate SEM.
Molecular Therapymonocytes embedded in the 3D device collagen gel after 48 hr of cul-
ture with pro-inﬂammatory cytokines (Figures S3E and S3F) and
even more strikingly after the addition of antigen-speciﬁc T cells
(Figure S3G).
By labeling the TCR-redirected T cells with a ﬂuorescent dye, we
were able to quantify their invasion into the hydrogel, observing
that this was increased by the presence of monocytes, but not by
PD-1 knockdown (Figure 5B). The recovery of TCR-redirected
T cells after co-culture and extraction from the microﬂuidic system
was likewise not affected by PD-1 knockdown (Figure 5C). Target
killing was assessed by the quantiﬁcation of live (GFP+) or dead
(DRAQ7-dye+) target cells after overnight co-culture with TCR-re-
directed T cells (Figures 5D and 5E). PD-1 knockdown signiﬁcantly
increased the efﬁciency of tumor cell killing with TCR-redirected
T cells from 2 donors, but not from the other 2 donors. With the
addition of PD-L1hi monocytes, the effect of PD-1 knockdown2558 Molecular Therapy Vol. 26 No 11 November 2018on augmenting T cell antitumor efﬁcacy became more consistent
(Figures 5D and 5E).
PD-1 Knockdown Drives Compensatory Pathways to Limit the
Persistence of Functional CD8 T Cells
The rationale to block the PD-1 co-inhibitory signal is based on its
prominent role in settings of persistent antigenic stimulation and re-
sulting T cell exhaustion. However, in vivo blockade and knockdown
studies in animal models and patients have revealed additional
complexity; PD-1 is just one of multiple non-redundant layers of
potential T cell co-inhibitors30 and may represent an adaptation
that facilitates long-term lymphocyte survival by curtailing excessive
stimulation.21,31–34 Therefore, we investigated potential negative con-
sequences of PD-1 genetic knockdown in human T cells from patients
with CHB exposed to further repetitive antigenic stimulation in vitro.
In this setting, PD-1 induced by persistent viral infection in vivo
would be expected to be further upregulated by in vitro restimulation
Figure 5. PD-1 Knockdown Boosts Antitumor Efficacy in PD-L1hi 3D HCC Cultures
(A) CD8+ T cells were isolated from healthy donors, transduced with LV-shCTR or LV-shPD-1, and expanded for 15 days. Representative flow cytometry data demonstrate
PD-1 knockdown efficiency and HBV-env T cell specificity after mRNA electroporation. A schematic of the DAX-1 3D microfluidic chip experimental timeline and design is
shown, where a represents the zoomed section, b represents the liquid channel region, and c represents the hydrogel region. (B) The number of T cells (+/ PD-1
(legend continued on next page)
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Figure 6. PD-1 Knockdown Drives Alternative Co-inhibitory and Senescence Program
Activated PBMCs from patients with CHB were transduced with LV-shCTR or LV-shPD-1 and then expanded with a-CD3/CD28 antibodies for 15 days. (A and B) Staining
and summary data of annexin V (A) (n = 8, CHB) and CTLA-4 (B) (n = 13, CHB) onGFP+CD8 T cells transduced with LV-shCTR or LV-shPD-1. (C) Example FACS plots of 2B4
and Tim-3 and Boolean gating analysis of the simultaneous expression of multiple inhibitory receptors (2B4, CTLA-4, and Tim-3) on GFP+ CD8 T cells transduced with
LV-shCTR or LV-shPD-1 (n = 5, CHB). Pie charts display the percentage of individual populations grouped according to 0–1 and 2–3 co-expressed inhibitory receptors. (D)
Expression and summary data of CD57 in GFP+ CD8 T cells (n = 13, CHB). All data were analyzed with Wilcoxon rank-sum test. CD8 T cells were pre-gated on live+/CD3+/
CD4. Significant differences are <0.1: *p < 0.05 and, ***p < 0.001. Any p value less than 0.001 was designated with three asterisks. Error bars indicate SEM.
Molecular Therapyin its role as a homeostatic regulator to curtail acute immune activa-
tion. Consistent with PD-1 providing a partially protective role, repet-
itively stimulated CD8 T cells with PD-1 knockdown showed
compensatory changes constraining their survival and function.
The FACS plots in Figure 6A exemplify the increase in the apoptotic
marker annexin V following repetitive stimulation of CD8 T cells
transduced with LV-shPD-1 compared to LV-shCTR. This suggested
that removal of PD-1 inhibition increased their susceptibility to acti-
vation-induced cell death (Figure 6A). We postulated that PD-1
knockdown in the presence of ongoing T cell stimulation might
also result in a compensatory increase in alternative co-inhibitory
pathways. In support of this, we found that the negative regulator
CTLA-4 was expressed at signiﬁcantly higher levels on CD8 T cells
on which PD-1 had been knocked down (Figure 6B). Combined anal-
ysis of CTLA-4, Tim-3 and 2B4 revealed that PD-1 knockdown CD8
T cells were more likely to co-express 2 or more of these co-inhibitory
molecules than T cells transduced with the control vector (Figure 6C).
We also observed an accumulation of CD57, a marker of end-stageknockdown) invading the region of interest was evaluated by confocal microscopy in the
analyzed with one-way ANOVA with Tukey’s test. (C) Percentage of HBV/HLA-A2 dextra
flow cytometry (n = 3). T cells were pre-gated on live+/CD14/CD3+/CD4. (D) Summa
the presence (top row) or absence (bottom row) of CD14+ cells (paired t test). The percen
staining and normalized to adjust for variable transduction of HBV TCR-expressing T cells
100% (a dot represents the percentage of killed targets in a single field). (E) Represent
PreS1 in green, dead cell staining DRAQ7 in red). Scale bars, 100 mm. Numbers of bas
death on day 2. Significant differences are <0.1: **p < 0.01 and ***p < 0.001. Any p va
2560 Molecular Therapy Vol. 26 No 11 November 2018differentiation toward immune senescence, on LV-shPD-1 CD8
T cells following repetitive rather than single restimulation (Figures
6D and S4). Altogether, these data reveal that PD-1 disruption on hu-
man CD8 T cells promotes upregulation of alternative pathways
driving terminal differentiation and premature cell death.
DISCUSSION
HCC is the second-leading cause of cancer deaths worldwide; better
treatments are urgently needed. Most cases arise on a background
of chronic cirrhotic liver disease, with organ function already
compromised. This provides a precarious backdrop in which to test
novel immune-boosting therapies such as checkpoint inhibitors.
Moreover, checkpoints such as the PD-1 pathway are strongly ex-
pressed on intrahepatic T cells and play a central role in maintaining
the uniquely immunotolerant state of the liver.11,21,35,36 Although
checkpoint blockade trials have begun in patients with HCC37 and
viral hepatitis,38,39 a more speciﬁc approach is desirable. The pivotal
role of PD-1 in maintaining peripheral tolerance40 places patientspresence or absence of autologous CD14+ cells in the hydrogel (n = 4). Data were
mer+CD3+ T cells recovered from the hydrogel 15 hr after co-culture, measured by
ry data of HBV-expressing HepG2 cell death by engineered T cells after co-culture in
tage of killed target cells (HepG2-PreS1-GFP) was evaluated by activation of DRAQ7
between donors, such that themean value for shCTRwithout monocytes was set to
ative confocal maximum intensity projections of the preceding conditions (HepG2-
eline dead cells in each device on day 1 were subtracted to calculate T cell-induced
lue less than 0.001 was designated with three asterisks. Error bars indicate SEM.
www.moleculartherapy.orgreceiving systemic blockade at risk of autoimmunity.7,41 Strong
expression of PD-1/PD-L1 within the tumor microenvironment
may predict a favorable response to PD-1 blockade41,42 but conversely
increases the risk of unleashing local collateral tissue damage.
In this study, we have demonstrated the feasibility of targeting trans-
duction toward low-frequency, endogenous antigen-speciﬁc or intra-
hepatic populations of T cells. We have shown that it is possible to
deliver lentiviral shRNA to these CD8 T cells to knock down PD-1
from high to negligible levels of expression. PD-1 knockdown has
similarly been achieved by alternative approaches such as CRISPR-
Cas9, zinc-ﬁnger nucleases, and transcription activator-like effector
nucleases (TALENs).43–46 However, the approach we developed al-
lows genetic editing of targets such as PD-1 to be focused on T cells
of desired speciﬁcity, making it possible to target low-frequency,
endogenously primed responses to tumor and viral antigens. Modi-
fying existing host-derived T cell responses ensures boosting of
relevant speciﬁcities without the need for cloning personalized
T cell receptors. However, in settings in which endogenous responses
are too low in frequency, we and others47,48 demonstrate that it is
feasible to instead modify checkpoints such as PD-1 on T cells that
have also undergone TCR gene transfer. We selected PD-1 because
it is a major regulator of peripheral tolerance and T cell exhaustion
in tumors and viral infections that is already being blocked in patients
with HCC.37 Our results provide a paradigm for combining genetic
optimization of both speciﬁcity and function and/or survival of
T cells in the setting of HBV-related HCC, which could be tested
on other molecular targets in the future.
PD-1 knockdown boosted some T cell functionality in 2D cultures,
but to better assess its impact on adoptive cancer immunotherapy,
we implemented a microﬂuidic model, recreating some characteris-
tics of a solid tumor microenvironment.28,29,49,50 These types of
models have gained attention as disease-relevant in vitro platforms,
enabling the identiﬁcation of human cell-cell interactions within a
controlled spatio-temporal environment.28,29,50,51 Because lysis of tu-
mor cells embedded in the 3D collagen microenvironment is a net
result of both the chemotactic characteristics and the intrinsic killing
capacity of the engineered TCR-redirected T cells, this assay mimics
more closely what is encountered physiologically during adoptive
T cell therapy of solid tumors, in which these parameters can be a crit-
ical determinant of antitumor efﬁciency. In this case, we speciﬁcally
recapitulated the high expression of PD-L1 that characterizes the liver
and tumor microenvironment by using prototypic proinﬂammatory
cytokines to induce this ligand on both the tumor and the added
monocytes. In this setting, we were able to demonstrate the beneﬁt
of PD-1 knockdown for boosting the efﬁciency with which TCR-re-
directed T cells kill an HBV antigen-expressing tumor. Future studies
could test efﬁcacy in animal models, as well as in early human trials of
genetically engineered T cells in HCC.50
A possible clinical limitation of this directed approach compared to
systemic PD-1 antibody blockade is that, paradoxically, non-T cell ef-
fects may be of some therapeutic beneﬁt. For example, a study showedthat systemic PD-1 blockade can inhibit melanoma cell-intrinsic
tumorigenesis, an effect mediated by PD-1-expressing cancer sub-
populations and independent of T cell PD-1.52 Our data demonstrate
additional caveats of targeting T cell PD-1, revealing that its knock-
down potentiates compensatory increases in other co-inhibitory
pathways such as CTLA-4 and Tim-3. Work from the lymphocytic
choriomeningitis virus (LCMV) mouse model of chronic viral infec-
tion and subsequent patient studies have shown that T cells are co-
regulated by multiple layers of inhibitory receptors;30,53–56 our new
data reveal that the expression of individual co-inhibitory receptors
can be cross-regulated. This suggests the need to knock down more
than one co-inhibitory receptor on T cells, in line with the enhanced
responses seen with use of dual checkpoint inhibitors in cancer
immunotherapy.1,3 The heterogeneity and non-redundancy of co-
inhibitory receptor hierarchies in patient populations may necessitate
personalized approaches.54–56 Larger studies are needed to test the
possibility that the variations in donor-to-donor efﬁcacy of PD-1
blockade we observed in the 3D model can predict responsiveness
in vivo. An alternative is to combine PD-1 silencing with
enhanced co-stimulation, as tested in a murine model of CAR
immunotherapy.15
In addition to providing insights for the reﬁnement of adoptive cell
therapy of HCC, our data underscore the multifaceted role of PD-1
on T cells. We ﬁnd enhancement of CD8 T cell cytolytic and non-
cytolytic antitumor potential following PD-1 knockdown in 2D and
3D cultures, in keeping with its well-accepted role in constraining re-
sponses. However, we observe that PD-1 also plays a protective role in
the setting of repetitive TCR-dependent stimulation; editing its
expression therefore accelerates T cell progression toward apoptosis
and end-stage differentiation. This extends to humans the data
from the LCMV mouse model, showing a similar pattern of prema-
ture cell death and senescence promoted by genetic deletion of
T cell PD-1.32 Although the detailed transcriptional and epigenetic
changes underpinning the compensatory alterations we observed
remain to be deﬁned, the associated induction of T-bet is in keeping
with early changes upon PD-1 knockdown noted in the LCMV
system32 and raises the possibility that lack of PD-1 may accelerate
T cell differentiation toward a short-lived effector subtype.57 Thus,
our data add to the accumulating body of evidence that PD-1-driven
T cell changes occurring during exhaustion constitute an adaptation
that allows T cells to withstand the onslaught of continual antigenic
stimulation while maintaining a degree of ongoing control.31–33
This is supported by our observations that high PD-1 expression is
a feature of long-lived, liver-resident T cells21 and of responses main-
taining viral control after treatment interruption in CHB.34 Alto-
gether, these ﬁndings argue that knockdown of PD-1 will be most
effective on short-lived T cell populations, because this could boost
their antitumor efﬁcacy while avoiding the limitation of premature
senescence upon repetitive stimulation. This could be applied in
the context of the tested approach for HBV-related HCC of
adoptive cell therapy with T cells that have their TCR speciﬁcity
redirected transiently by mRNA electroporation (ClinicalTrials.gov:
NCT02686372 and NCT02719782).49,50,58Molecular Therapy Vol. 26 No 11 November 2018 2561
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T cells speciﬁc for viral tumor-related antigens from the periphery
and liver of patients with CHB. Although technically challenging,
the extraction and transduction of liver-resident T cells could exploit
their speciﬁc adaptations. However, whether this strategy would pro-
mote their long-term survival at the site of hepatic tumors remains to
be tested. Our data provide the proof of principle of the capacity to
preferentially target and modify antigen-speciﬁc T cells using either
endogenous or TCR-redirected T cells. PD-1 downregulation in-
creases antitumor cytotoxicity and proliferation but also drives
long-term over-activation, resulting in a phenotype with features of
apoptosis and accelerated differentiation. Thus, our more focused
approach could overcome some problems with systemic PD-1
blockade but uncovers residual limitations related to the complex
role of this co-inhibitory receptor in T cells. Our work highlights
the need for more fundamental editing of genomic and non-coding
mediators of T cell exhaustion to reﬁne adoptive cell therapy for
persistent viral infections and cancers. The identiﬁcation of distinct
enhancers differentiating the upregulation of PD-1 in acutely acti-
vated T cells, as opposed to chronically exhausted T cells, provides
scope for future state-speciﬁc modulation.59 In the interim, the
enhanced immediate tumor killing we show in a novel microﬂuidic
3D-model supports consideration of combining PD-1 knockdown
with TCR gene transfer for adoptive cell therapy trials in patients
with HCC.
MATERIALS AND METHODS
Subjects and Sample Collection
This study was approved by the local ethical boards of London-Brent
(Regional Ethics Committee reference number 16/LO/1699) and
Brighton and Sussex (Research Ethics Committee reference number
11/LO/0421) (IRAS Project ID 43993) and the Institutional Review
Board of the National University of Singapore. Liver resections and
perfusions were obtained through the Tissue Access for Patient
Beneﬁt Scheme, approved by the Royal Free Hospital Biobank Ethical
Committee (references 11/WA/0077 and 11/H0720/4). A total of
thirty-eight chronic HBV patients and nine healthy volunteers partic-
ipated in the study. All participants were HCV and HIV sero-negative
and treatment naive. PBMCs were separated using Ficoll-Paque Plus
(GE Healthcare) density gradient centrifugation and cryopreserved.
Liver sections from ﬁve CHB biopsies, two CHB liver resections,
and four healthy margins from colorectal metastasis resections were
obtained. Seven transplant perfusates from cadaveric donor livers
were collected during liver transplant surgery under the standard
graft preparation protocols.
Cell Lines
T2 cells were cultured in RPMI 1640 (Life Technologies) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS),
0.5 mM sodium pyruvate, 100 U/mL penicillin, 100 mg/mL strepto-
mycin, and GlutaMAX. Phoenix and HEK293T were grown
in DMEM (Life Technologies), 10% FBS, 100 U/mL penicillin,
100 mg/mL streptomycin, and GlutaMAX. HepG2preS1 cells express-
ing the full genotype D envelope gene linked to GFP were obtained as2562 Molecular Therapy Vol. 26 No 11 November 2018described28 and maintained in DMEM with 10% heat-inactivated
FBS, 20 mMHEPES, 0.5 mM sodium pyruvate, 100 IU/mL penicillin,
100 mg/mL streptomycin, and 5 mg/mL Plasmocin (InvivoGen), with
5 mg/mL puromycin (Clontech) to select for transgene-expressing
target cells.
Lentiviral Vector Production
The pHIV1-SIREN lentiviral vector (LV-shRNA) expressing
PD-1-speciﬁc shRNA (50-GTGCTAAACTGGTACCGCAT-30) un-
der a U6 promoter and encoding for EGFP under a phosphoglycerate
kinase (PGK) promoter was described previously.60 LV-shCTR was
generated, replacing the shPD-1 sequence for a control shRNA
(50-CCTAAGGTTAAGTCGCCCTCG-30), and mCherry constructs
were generated by GenScript (USA). Three-plasmid co-transfection
into HEK293T cells was used to make VSV-g pseudotyped lentivirus.
The 12e6 HEK293T cells were seeded in 150-mm plates; 24 hr later,
they were transfected using Fugene6 (Promega) with the following the
plasmids: 3.75 mg SIN pHV (vector plasmid), 2.5 mg p8.91 (Gag-Pol
expression plasmid), and 2.5 mg pMD.G (VSV-g env expression
plasmid). Supernatant was collected over 24-hr periods for
3 days. Following collection, LV supernatant was passed through a
0.45-mm ﬁlter and concentrated by ultracentrifugation in a SureSpin
630 rotor (Thermo Scientiﬁc, Waltham, MA) through a 25% sucrose
cushion at 25.000 rpm for 2 hr at 4C. The pellet was resuspended in
PBS and stored at 80C. Lentivirus vectors were added at a MOI of
20. Lentivectors were titrated as described.60
Lentiviral Transduction Protocol for Antigen-Specific
CD8 T Cells
PBMCs from HLA-A2+ healthy donors and CHB patients were
isolated by Ficoll-Hypaque gradient separation (Lymphoprep)
and enriched for CD8+ cells with the human CD8 MicroBead
Isolation Kit (Miltenyi Biotec) following the manufacturer’s in-
structions. CD8 T cells were stimulated with the following peptides
for 24 hr in RPMI-10% FBS supplemented with IL-2 (20 U/mL) in
the presence or absence of IL-15 (10 ng/mL, R&D): 1 mM HBV-
derived HLA-A2-restricted epitopes (core FLPSDFFPSV; envelope
FLLTRILTI, WLSLLVPFV, LLVPFVQWFV, and GLSPTVWLSV;
and polymerase GLSRYVARL and KLHLYSHPI) (Proimmune)
and 1 mM NLVPMVATV (Proimmune). Lentiviral vectors were
added 24 hr after stimulation, and media were replaced with
RPMI-10% FBS plus IL-2 (20 U/mL) 72 hr later. Functional
studies were carried out 5 days post-transduction. T2 cells were
loaded with 1 mg/mL HBV or CMV peptides for 1 hr at 37C,
washed, and co-cultured with lentivirally modiﬁed T cells
(ratio 1:1) overnight in RPMI-10% FBS with 1 mg/mL brefeldin
A (BFA) (Sigma). GFP and mCherry expression were used as
markers for lentiviral transduction. Virus-speciﬁc responses were
identiﬁed by IFN-g production. Whole PBMCs from patients
with CHB were stimulated for 24 hr, with 1 mM overlapping pep-
tides (OLPs) spanning the whole HBV core protein, genotype
D (AYW) (JPT Peptide Technologies) in the presence of IL-15
(10 ng/mL). On day 9, PBMCs were restimulated with 1 mM
OLPs in the presence of BFA.
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The antigen-speciﬁc encoding for HBc18–27-speciﬁc TCR Va3/Vb8.2
chains (c18-TCR), the HBs183-91-speciﬁc TCR (s183-TCR) Va34/
Vb28, and the amphotropic envelope plasmid (pCMV-Ampho)
were described previously.14,25 15e6 Phoenix amphotropic packaging
cells were seeded into 150-mm tissue culture dishes 24 hr before
transfection. Phoenix cells were transiently co-transfected using
Fugene6 (Promega) with 3.75 mg of MP71-TCR, together with
2.5 mg of pCMV-Ampho. 24 hr later, DMEM was replaced with fresh
medium and retroviral supernatants were collected and spun down
72 hr after transfection. PBMC were stimulated with 600 U/mL
IL-2 (PeproTech), 0.5 mg/mL plate-bound a-CD3 (OKT-3;
eBioscience), and 1 mg/mL a-CD28 for 48 hr. Untreated 24-well tissue
culture plates were coated with 30 mg/mL RetroNectin (Takara Bio)
overnight at 4C one day before transduction. Wells were then
washed with PBS and blocked with PBS 2% BSA. 1.5–2 mL of retro-
viral supernatant was added per well and spun down at 2,000  g for
2 hr at 37C. Lymphocytes were harvested, washed, and counted, and
1e6 cells were plated into RetroNectin-coated wells with IL-2
(600 U/mL) and mixed with the retroviral supernatant. After 24 hr,
medium was replaced and cells were maintained in RPMI-10% FBS
plus 100 U/mL IL-2. TCR surface expression was tested with HLA-
A201-HBc18-27-PE and HLA-A201-HBe183-91-PE dextramers
(Proimmune) or anti-Cb antibodies 3–5 days after transduction.
Functionality of TCR-redirected T cells was tested 7 days after trans-
duction, as described later. Flow cytometry was performed using a
FACS LSRII and Fortessa ﬂow cytometer (BD Biosciences), and
data were analyzed with the FACS Diva program (BD Biosciences).
In some cases, HBV TCR retrovirus supernatant was concentrated
and titrated as described for lentiviral particles and frozen at 80C.
RNA Extraction and Real-Time qPCR
PBMCs from healthy donors were lentivirally transduced with LV-
shCTR-mCherry and LV-shPD-1-mCherry following the previously
described protocol. mCherry+ CD8+ and CD4+ T cells were sorted
in a BD FACS Aria, and cell pellets used for RNA extraction with
the RNeasy micro-RNA Puriﬁcation Kit (QIAGEN). Retrotranscrip-
tion was performed with the iScript cDNA Synthesis kit (Bio-Rad).
PD-1 expression was quantiﬁed using IQ SYBR Green Supermix
(Bio-Rad) in the Roche LightCycler-480 qPCR machine, with B-actin
expression for normalization.
Intrahepatic Lymphocyte Isolation and Lentiviral Transduction
Liver tissue was digested using enzymes (1 ng/mL collagenase IV and
0.1 ng/mL DNase I) and mechanical maceration before passing
through a 70-mm cell strainer. Intrahepatic leukocytes isolated from
liver biopsies were used immediately, whereas those isolated from
larger liver tissue and perfusates were isolated with an extra Percoll
density centrifugation step before experimentation. T cells from
non-HBV livers were activated for 24 hr with IL-15 and IL-7
(10 ng/mL) before the addition of LV particles, whereas T cells
from CHB samples were activated with 1 mM HBV core OLPs or
HLA-A2-restricted HBV peptides for HLA-A2+ CHB patients plus
IL-15 and IL-7 (10 ng/mL) and IL-2 (20 IU/mL). 72 hr after activa-tion, media were replaced by maintaining media (MM) containing
RPMI-10% FBS with IL-2 (100 U/mL) and IL-15 and IL-7 (5 ng/mL).
Generation of shPD-1/HBV TCR CD8 T Cells
TCR-redirected CD8 T cells from healthy controls were sorted based
on TCR Cb expression in FACS Aria (BD Biosciences) and expanded
with IL-2 (100 U/mL) and IL-15 and IL-7 (5 ng/mL). After 1–2 weeks,
CD8 T cells were lentivirally transduced after 24 hr of stimulation
with 0.5 mg/mL plate-bound a-CD3 (OKT-3; eBioscience) and
1 mg/mL a-CD28 plus IL-2 (600 U/mL) and IL-15 and IL-7
(10 ng/mL). Three days after activation, media were replaced with
MM, and functional analysis was performed 5–7 days after lentiviral
transduction.
Function of TCR-Transduced T Cells
Redirected T cell functionality was tested 7 days after transduction.
HLA-A0201 T2 cells were loaded with 1 mg/mL of each peptide for
1 hr at 37C, washed, and co-cultured with TCR-redirected T cells
overnight in RPMI-10% FBS with 1 mg/mL BFA (Sigma) in a 1:1 ratio.
Production of s183–191 TCR mRNA and Electroporation
Procedures
HBV-env183-191TCR mRNA was obtained as described.
49 HBV-
env183-91-speciﬁc TCR DNA was subcloned into the pVAX1 vector,
linearized using FastDigest XbaI (Thermo Fisher Scientiﬁc), and
used to produce the TCR-mRNA using the Ambion mMESSAGE
mMACHINE T7 Ultra kit (Thermo Fisher Scientiﬁc). For electropo-
ration with the nucleofector device (BTX, Agilpulse Max), 5e106–
10e106 peripheral blood mononuclear cells were activated for 24 hr
with 0.5 mg/mL plate-bound a-CD3 (OKT-3; eBioscience) and
1 mg/mL a-CD28 plus IL-2 (600 U/mL) and IL-15 and IL-7 (10 ng/
mL) in AIM-V 2% human AB serum. Lentiviral vectors were added
24 hr after stimulation with a MOI of 10, and media were replaced
on day 3 with AIM-V 2% human AB serum plus 100 U/mL IL-2.
PBMCs were activated on day 7 under the same conditions. On day
13, PBMCs were placed overnight with AIM-V 2% human AB serum
plus 1,000 U/mL IL-2. On day 14, PBMCs were resuspended in 100–
200 mL of Cell Line Nucleofector Solution V (Lonza) and TCRmRNA
was added at 100 mg/mL. Themixture was placed in a certiﬁed cuvette
(BTX) and electroporated. After electroporation, cells were resus-
pended in AIM-V 2% human AB serum plus 100 IU/mL recombinant
IL-2 (rIL-2).
Staining for Multimer+ T Cells and Intracellular Cytokine
Production
HBV-speciﬁc T cells were identiﬁed with a pool of HLA-A2/peptide
dextramers: core FLPSDFFPSV; envelope FLLTRILTI, WLSLLVPFV,
and GLSPTVWLSV; and polymerase GLSRYVARL and
KLHLYSHPI. CMV-speciﬁc dextramers were loaded with
NLVPMVATV. Cells were stained with dextramers, washed, and res-
ted for 30 min before proceeding to ﬂow cytometry analysis or were
stimulated with peptide-loaded T2 cells for 1 hr before the addition of
BFA in a 1:1 ratio. After 5 hr of incubation, cells were stained with the
surface marker antibodies, live-dead staining and anti-CD19Molecular Therapy Vol. 26 No 11 November 2018 2563
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respectively. Intracellular cytokines were detected as described.
Functional Studies
PBMCs from CHB patients were stimulated for 24 hr with 0.5 mg/mL
plate-bound a-CD3 and 1 mg/mL a-CD28 (eBioscience) before the
addition of lentiviral particles. Three days after activation, media
were changed with fresh media containing IL-15 and IL-7
(5 ng/mL). Seven days after lentiviral transduction, T cells were
expanded with a-CD3/CD28 antibodies. Fifteen days after lentiviral
transduction, overnight restimulation was carried out in the presence
of 1 mg/mL BFA. All cultures were carried out in the presence of 20
IU/mL recombinant human IL-2 (Miltenyi Biotec) in RPMI-10%
FBS at 37C.
Flow Cytometric Analysis
9- or 12-color ﬂow cytometry was used for all experiments. Dead cells
were always excluded using a live-dead ﬁxable dye staining kit (Invi-
trogen). Cells were stained for surface markers CD3, CD4, CD8
(eBioscience), PD-1 (BioLegend), 2B4, Tim3, CD57, VBm, PD-L1,
and CD14. Cells were then ﬁxed and permeabilized, and intracellular
molecules were detected using anti-IFN-g, TNF-a, granzyme B, and
CTLA-4. For annexin V quantiﬁcation, following surface marker
staining and live-dead staining, cells were washed and annexin V
staining was performed in annexin V binding buffer (BioLegend).
For Ki67 intracellular or nuclear staining, ﬁxation was performed
with CytoFix buffer (BD Biosciences) and permeabilization using
0.01%TritonX-100 solution. All sampleswere acquired on aBDLSRII
or BD Fortessa. All analysis was performed using FlowJo (Tree Star).
3D Microdevice Assay
The embedding of HepG2-preS1 targets andmonocytes inmicrodevi-
ces was described previously.28,29 A commercially available microﬂui-
dic device (DAX-1, AIM Biotech) was used to co-culture genetically
modiﬁed T cells with HepG2-preS1 and in the presence or absence
of CD14+ cells. Two collagen hydrogels were prepared for injection
in the dedicated microﬂuidic region: (1) 2.5 mg/mL type I collagen
gel solution containing 20 mL homogenously dissociated freshly tryp-
sinized HepGpreS1 at 50e6 cells/mL, mixed with 20 mL 10 PBS, 4 mL
NaOH (0.5N), 129.2mL collagen type I (Corning), and 22.9mL cell cul-
ture water, and (2) the preceding hydrogel with the addition of CD14+
cells (isolated from freshPBMCswith aCD14microbead kit according
to manufacturer’s instructions), and 20 mL of a 50e6 cells/mL labeled
cell solution (orange CMRA, Thermo Fisher Scientiﬁc). 10 mL hydro-
gel master mix was used for injection in the dedicated device region,
maintained in the holder at 37C for 40 min to allow for gel polymer-
ization by thermal cross-linking. After gel polymerization, media
channels were ﬁlled with complete RPMI in the presence or absence
of 1,000 U/mL IFN-g, 100 ng/mL TNF-a, and 100 U/mL IL-2.
DRAQ7 (BioLegend) was added to the media at a concentration of
3 mM to discriminate between live and dead cells. Devices were incu-
bated for 24 hr to permit interaction of HepG2preS1 target cells with
collagenmatrix and set themicroenvironment. TCR-redirected T cells
(shPD-1 or shCTR), labeled with 3 mM CellTracker Violet BMQC2564 Molecular Therapy Vol. 26 No 11 November 2018(Life Technologies, Carlsbad, CA) resuspended in RPMI-10% FBS at
6e6 cells/mL, were added (30 mL) into one of the two media channels
ﬂanking the central gel region of each device and incubated for 15 hr at
37C before image acquisition.
3D Device Imaging and Data Analysis
Confocal images of constant hydrogel regions were taken on day 1
before the addition of T cells and 24 hr after T cell injection in the
device. The images were acquired with either LSM7800 confocal
microscopy (Zeiss) or high-content imaging-system (Operetta,
PerkinElmer) and analyzed using Imaris software (Bitplane) to quan-
tify dead targets before and after T cell addition. Live targets were
recognized by GFP expression in green, dead cells were identiﬁed
by DRAQ7 in red, T cells were labeled with BMQC in blue, and
CD14+ cells were labeled with orange CMRA stain. The number of
killed targets was calculated by subtraction of baseline dead cells
before T cell addition and normalized to allow comparison between
donors with variable amounts of HBV TCR expression, such that
the baseline control condition was set to 100%.
Extraction of Cells from the 3D Device
Media from the 3D device ports were replaced by a solution of
1 mg/mL collagenase type II (Gibco) and incubated for 5 min at
37C, and then cell suspensions were extracted from the gel and me-
dia channels. The 3D device was washed once with PBS to ﬂush out
remaining cells. Cells were then washed with PBS and stained for
ﬂow cytometry.
Statistical Analysis
Statistical analyses were performed using one-way ANOVA, Stu-
dent’s t test and Tukey’s test, the non-parametric Wilcoxon matched
pairs test, Friedman test and Dunn’s multiple comparison tests, and
Pearson product-moment correlation coefﬁcient as appropriate. Sig-
niﬁcant differences were marked in ﬁgures legends: yp < 0.1, *p < 0.05,
**p < 0.01, and ***p < 0.001. Any p value less than 0.001 was desig-
nated with three asterisks.
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